Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy is a multi-component analgesic and anti-inflammatory formulation used primarily for the treatment of postherpetic neuralgia (PHN). It consists of lidocaine, a local anesthetic; triamcinolone acetonide, a synthetic corticosteroid; and vitamin B12 (often as cyanocobalamin or methylcobalamin). Lidocaine provides rapid pain relief by blocking voltage-gated sodium channels, thereby inhibiting the conduction of nerve impulses. Triamcinolone acetonide acts as a potent anti-inflammatory agent by activating glucocorticoid receptors, which helps to reduce local edema and inflammation around the affected nerves. Vitamin B12 is included to support nerve health, promoting myelination and the repair of damaged nerve fibers. The combination is typically administered via local infiltration or nerve block to target the site of neuropathic pain directly, aiming to provide both immediate symptomatic relief and long-term improvement in nerve function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + triamcinolone acetonide + vitamin b12.